BAKU, Azerbaijan, Feb. 23
By Klavdiya Romakayeva - Trend:
Uzbekistan and Egypt signed agreements regarding an investment project on launching production of solid dosage forms in the form of tablets, hard gelatin capsules and dosed powders, Trend reports referring to the pharmaceutical industry development agency of Uzbekistan.
According to the information, the joint project will be implemented within the framework of the agreements reached following the official visit of the President of Egypt Abdel Fattah Al-Sisi to Uzbekistan in September 2018.
It is noted that the agreement on the implementation of the investment project was signed by Deputy governor of the Tashkent region Jamshid Abdusalomov, Director of the Agency for the Development of the Pharmaceutical Industry Sardor Kariev and President of Solyphar Omar Abdel El-Alem.
Director of the Agency for Development of the Pharmaceutical Industry Sardor Kariev said that the joint project envisages the construction of a new facility in the Tashkent region worth more than $20 million.
It is reported that the annual production capacity will be 500 million tablets, 200 million capsules and 10 million sachets, totaling more than 120 types of drugs. It was also noted that the new production will meet the requirements of Good Manufacturing Practice (GMP).
In addition, more than 200 new jobs will be created due to the launch of the facility. It is also planned to organize training of local specialists for production of high-quality products through the introduction of new and advanced technologies.
Solyphar is a limited liability company, which started its activity for exporting and marketing pharmaceuticals in 2015, which derived from ADMA Co which has been established in 2002 to export pharmaceutical products and paramedical mainly to the CIS region.
Currently, Solyphar is one of the leading Egyptian companies acting as exclusive agent for some Pharmaceutical companies with portfolio of around 400 products of pharmaceuticals, food supplements, veterinary products, and paramedicals, representing around 10 factories, and located in more than 12 countries through its representatives and scientific offices.
Follow the author on Twitter: @romakayeva